S. Phan

3.6k citations

43 papers · 2.5k indexed · 2 hit papers · h-index 15

Impact in

Oncology top 2%
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
Genetics top 2%
- Glioma Diagnosis and Treatment

Papers in ⓘ

Pulmonary and Respiratory Medicine 31
- Brain Metastases and Treatment 13
- Lung Cancer Treatments and Mutations 10
- Advanced Breast Cancer Therapies 7
Oncology 31
- Cancer Treatment and Pharmacology 15
- Lung Cancer Research Studies 10
- Cancer Immunotherapy and Biomarkers 6

Co-authors: Adam Brufsky (7 shared papers)Edith A. Perez (2 shared papers)Véronique Dièras (7 shared papers)John A. Glaspy (6 shared papers)Oleg Lipatov (4 shared papers)Nicholas J. Robert (5 shared papers)Igor Bondarenko (4 shared papers)Joyce O’Shaughnessy (4 shared papers)
Journals: Journal of Clinical Oncology (18 papers)International Journal of Radiation Oncology*Biology*Physics (7 papers)Annals of Oncology (6 papers)Journal of Thoracic Oncology (4 papers)ESMO Open (1 paper)
Partner nations: United States France Canada

In The Last Decade

S. Phan

43 papers receiving 2.4k citations

Hit Papers

align trajectories log scale

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer 2013 · 370 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2013 Journal of Clinical Oncology
2011 Journal of Clinical Oncology

Peers

Countries citing papers authored by S. Phan

Since Specialization

Citations

This map shows the geographic impact of S. Phan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Phan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Phan more than expected).

Fields of papers citing papers by S. Phan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Phan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Phan. The network helps show where S. Phan may publish in the future.

Co-authors

The 25 scholars most cited alongside S. Phan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with S. Phan Line = papers co-authored together S. Phan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 43 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer Journal of Clinical Oncology ·Nicholas J. Robert, Véronique Dièras, John A. Glaspy, Adam Brufsky, Igor Bondarenko, Oleg Lipatov, Edith A. Perez, Denise A. Yardley, Stephen Chan, Xian Zhou, S. Phan, Joyce O’Shaughnessy Hit paper breakdown →	2011	766
2	Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial Journal of Clinical Oncology ·Christina A. Meyers, Jennifer A. Smith, Andrea Bezjak, Minesh P. Mehta, James Liebmann, Tim Illidge, Ian Kunkler, J. Caudrelier, Peter D. Eisenberg, J.H. Meerwaldt, Ross Siemers, C. Carrié, Laurie E. Gaspar, Walter J. Curran, S. Phan, Richard Miller, Markus F. Renschler	2003	423
3	Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer Journal of Clinical Oncology ·David R. Spigel, Thomas J. Ervin, Rodryg Ramlau, Davey B. Daniel, Jerome H. Goldschmidt, George R. Blumenschein, Maciej Krzakowski, G. Robinet, B. Godbert, Fabrice Barlési, Ramaswamy Govindan, Taral Patel, С. В. Орлов, M. S. Wertheim, Wei Yu, Jiping Zha, Robert L. Yauch, Premal H. Patel, S. Phan, Amy Peterson Hit paper breakdown →	2013	370
4	Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain Metastases Journal of Clinical Oncology ·Minesh P. Mehta, Patrick Rodrigus, C. Terhaard, Aroor R. Rao, John H. Suh, Wilson Roa, Luís Souhami, Andrea Bezjak, Mark H. Leibenhaut, Ritsuko Komaki, Christopher G. Schultz, Robert Timmerman, Walter J. Curran, Jennifer A. Smith, S. Phan, Richard Miller, Markus F. Renschler	2003	351
5	A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). Journal of Clinical Oncology ·J. O’Shaughnessy, David Miles, Robert J. Gray, V. Diéras, Edith A. Perez, Robin Zoň, Javier Cortés, Xueying Zhou, S. Phan, K. Miller	2010	83
6	Phase II Trial of Anastrozole Plus Goserelin in the Treatment of Hormone Receptor–Positive, Metastatic Carcinoma of the Breast in Premenopausal Women Journal of Clinical Oncology ·Robert W. Carlson, Richard L. Theriault, Christine M. Schurman, Edgardo Rivera, Cathie T. Chung, S. Phan, Banu Arun, Kristine Dice, Vivian Chiv, Marjorie Green, Vicente Valero	2010	69
7	IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC) Annals of Oncology ·M. Reck, Stephen V. Liu, Aaron S. Mansfield, Tony Mok, Arnaud Scherpereel, Niels Reinmuth, Marina Chiara Garassino, J. De Castro Carpeño, Raffaele Califano, Makoto Nishio, Francesco Orlandi, Jorge Arturo Alatorre Alexander, Ticiana Leal, Ying Cheng, J.-S. Lee, S. Lam, Mark L. McCleland, Yu Deng, S. Phan, Leora Horn	2019	49
8	Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC) Annals of Oncology ·E.S. Kim, Vamsidhar Velcheti, Tarek Mekhail, Ticiana Leal, J.E. Dowell, Ming-Hung Tsai, Christopher Dakhil, Philip J. Stella, Vincent K. Shen, Sylvia Hu, S.M. Paul, David S. Shames, Erica Schleifman, D.A. Fabrizio, C. Yun, S. Phan, Mark A. Socinski	2018	47
9	Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC) Annals of Oncology ·Mark A. Socinski, Vamsidhar Velcheti, Tarek Mekhail, Y.K. Chae, Ticiana Leal, J.E. Dowell, Ming-Hung Tsai, Christopher Dakhil, Philip J. Stella, Vincent K. Shen, Sylvia Hu, S.M. Paul, David S. Shames, Erica Schleifman, David Fabrizio, Michaeł Nowicki, C. Yun, S. Phan, E.S. Kim	2019	41
10	5016 Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) European Journal of Cancer Supplements ·Véronique Dièras, John A. Glaspy, Adam Brufsky, Igor Bondarenko, Oleg Lipatov, EA Perez, Sik-Kwan Chan, Xuan Zhou, S. Phan, Nicholas J. Robert	2009	34
11	Clinical Benefit Rate and Time to Response in RIBBON-1, a Randomized, Double-Blind, Phase III Trial of Chemotherapy with or without Bevacizumab (B) for the First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (MBC). Cancer Research ·Nicholas J. Robert, Véronique Dièras, John A. Glaspy, Adam Brufsky, Igor Bondarenko, Oleg Lipatov, EA Perez, DA Yardley, S. Phan, Somshuvra Bhattacharya, Joyce O’Shaughnessy	2009	33
12	Results of the Phase I Dose-Escalating Study of Motexafin Gadolinium With Standard Radiotherapy in Patients With Glioblastoma Multiforme International Journal of Radiation OncologyBiologyPhysics ·Judith Ford, Wendy Seiferheld, Jeffrey Alger, Genevieve N. Wu, T.J. Endicott, Minesh P. Mehta, Walter J. Curran, S. Phan	2007	29
13	Phase I Trial of Motexafin Gadolinium in Combination with Docetaxel and Cisplatin for the Treatment of Non-small Cell Lung Cancer Journal of Thoracic Oncology ·William N. William, Ralph Zinner, Daniel D. Karp, Yun Oh, Bonnie S. Glisson, S. Phan, David J. Stewart	2007	22
14	OA01.06 DETERRED: Phase II Trial Combining Atezolizumab Concurrently with Chemoradiation Therapy in Locally Advanced Non-Small Cell Lung Cancer Journal of Thoracic Oncology ·Steven H. Lin, Lin Xiao, Daniel L. Clay, Luyang Yao, Isabel Mok, Daniel R. Gomez, Jonathan M. Kurie, George R. Simon, George R. Blumenschein, Jenean A. Young, S. Phan, A. Sandler, Vassiliki A. Papadimitrakopoulou, John V. Heymach, Anne S. Tsao	2018	20
15	Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a phase III trial Journal of Clinical Oncology ·Minesh P. Mehta, R. Gervais, Pierre Chabot, William R. Shapiro, Roy A. Patchell, Michael Glantz, Lawrence D. Recht, S. Phan, Jennifer A. Smith, Markus F. Renschler	2006	20
16	Blood first line ready screening trial (B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastatic NSCLC Annals of Oncology ·Tony Mok, Shirish M. Gadgeel, E.S. Kim, Vamsidhar Velcheti, Sylvia Hu, Todd Riehl, Erica Schleifman, Satabdi Paul, Simonetta Mocci, David S. Shames, S. Phan, C. Yun, Mariann Mathisen, Marcin Kowanetz, U. Sweere, Mark A. Socinski	2017	12
17	MA04.09 Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Multicenter Study (LCMC3) Journal of Thoracic Oncology ·Valerie W. Rusch, Jamie E. Chaft, Bruce E. Johnson, Ignacio I. Wistuba, Mark G. Kris, J. Lee, Paul A. Bunn, David J. Kwiatkowski, Karen L. Reckamp, David J. Finley, Eric B. Haura, Saiama N. Waqar, Robert C. Doebele, Edward B. Garon, Justin D. Blasberg, A. Nicholas, K. Schulze, S. Phan, M. Gandhi, David P. Carbone	2018	9
18	375O Final efficacy results from IMpower132: First-line atezolizumab + chemotherapy in patients with stage IV non-squamous NSCLC Annals of Oncology ·MAKI NISHIO, Fabrice Barlési, S. Ball, Rodolfo Bordoni, Manuel Cobo, Pascale Dubray‐Longeras, Jerome H. Goldschmidt, Silvia Novello, F. Orlandi, Rachel E. Sanborn, Zsuzsanna Szalai, G. Ursol, Diana Mendus, L. Wang, Xingqiao Wen, Mark L. McCleland, Tien Hoang, S. Phan, Mark A. Socinski	2020	9
19	Goserelin plus anastrozole in the treatment of premenopausal hormone receptor positive, recurrent or metastatic breast cancer Journal of Clinical Oncology ·R. W. Carlson, Christine M. Schurman, E. Rivera, Cathie T. Chung, S. Phan, E. K. Dice, E. Donnall Thomas, Vicente Valero	2007	9
20	FP13.03 IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1–Selected NSCLC Journal of Thoracic Oncology ·Roy S. Herbst, Filippo de Marinis, Giuseppe Giaccone, A. Vergnenègre, Carlos H. Barrios, Masahiro Morise, Enriqueta Felip, Cristina Oprean, Y. Kim, Zoran Andrić, Simonetta Mocci, Ida Enquist, K.M. Komatsubara, Mark L. McCleland, Yu Deng, Hiroshi Kuriki, Matthias Villalobos, S. Phan, David R. Spigel, Jacek Jassem	2021	8

About S. Phan

S. Phan is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research and Genetics, having authored 43 papers that have together received 2.5k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (15 papers), Brain Metastases and Treatment (13 papers), Lung Cancer Research Studies (10 papers), Lung Cancer Treatments and Mutations (10 papers), Advanced Breast Cancer Therapies (7 papers), Cancer therapeutics and mechanisms (6 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Glioma Diagnosis and Treatment (6 papers). The work is most often cited by research in Oncology (1.6k citations), Genetics (547 citations), Pulmonary and Respiratory Medicine (1.4k citations), Cancer Research (525 citations) and Hepatology (167 citations). S. Phan has collaborated with scholars based in United States, France and Canada. Frequent co-authors include Adam Brufsky, Edith A. Perez, Véronique Dièras, John A. Glaspy, Oleg Lipatov, Nicholas J. Robert, Igor Bondarenko, Joyce O’Shaughnessy, Xian Zhou and Stephen Chan. Their work appears in journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics, Annals of Oncology, Journal of Thoracic Oncology and ESMO Open.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact